Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
Top Cited Papers
- 20 October 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 9 (5), 467-475
- https://doi.org/10.1016/s2213-2600(20)30391-x
Abstract
No abstract availableFunding Information
- Merck Sharp and Dohme
This publication has 20 references indexed in Scilit:
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 BlockadeClinical Cancer Research, 2017
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicityNature Communications, 2017
- Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJCI Insight, 2014
- Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell ImmunotherapyCancer Cell, 2013
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast CancerClinical Cancer Research, 2005
- Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediatedInternational Journal of Radiation Oncology*Biology*Physics, 2004